Dermata Therapeutics, Inc. (DRMAW) 주식 분석

회사 개요

Dermata Therapeutics, Inc. (DRMAW) operates as a late-stage medical dermatology company dedicated to the identification, development, and commercialization of pharmaceutical product candidates designed for the treatment of medical skin diseases and aesthetic applications. Although specific sector and industry classifications are not publicly disclosed in the provided data, the company's focus on dermatological therapies places it within the specialized pharmaceutical and biotechnology landscape where regulatory pathways and clinical trial timelines are critical success factors. The company maintains a lean organizational structure with a total of 9 employees, which is typical for biopharma firms in the pre-commercialization or late-stage development phases that rely heavily on external partnerships or specialized clinical networks. The absence of reported market cap and annual revenue figures in the available data suggests that the company may be a micro-cap entity or a pre-revenue biotech firm where traditional valuation metrics are not yet applicable due to the nature of its development pipeline. This lack of revenue data indicates that the company's current value is primarily derived from its intellectual property, specifically its lead product candidate XYNGARI, rather than from generated sales, which is a common characteristic for late-stage medical companies awaiting regulatory approval or market entry.

재무 건전성

The company reported a net income of $-7,558,557 for the trailing twelve months (TTM), while revenue and EBITDA figures are not available in the current dataset, creating a significant gap that reveals a heavy cost structure typical of drug development activities where R&D expenses far exceed current sales. The free cash flow stands at $-5,016,645, indicating that the company is burning through cash reserves to fund its operations and development efforts, which limits immediate financial flexibility but is a necessary expenditure for bringing a product candidate like XYNGARI to market. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, a figure that reflects the absence of revenue or a scenario where costs completely erode gross sales, resulting in no profitability at the gross or operating level. Despite the negative earnings, the balance sheet shows a cash position of $7.52M contrasted against $0 in debt, suggesting a conservative capital structure with no leverage and no interest obligations to pressure cash flow. The current ratio of 4.79 indicates a strong short-term liquidity position relative to current liabilities, providing a substantial buffer to cover operational expenses and clinical trial costs over the coming quarters. Return on Equity is -194.2% and Return on Assets is -85.3%, metrics that highlight the company's current inability to generate positive returns on shareholder or asset investments due to the cumulative nature of its losses and the early stage of its commercialization efforts.

밸류에이션 평가

Trailing P/E, forward P/E, and price-to-sales ratios are listed as N/A, meaning standard earnings-based valuation methods cannot be applied to DRMAW at this time, and the absence of these metrics implies that investors must rely on asset-based or pipeline-based valuation models rather than traditional multiples. The price-to-book ratio is recorded at 0.01, which indicates that the market capitalization is significantly below the company's book value, suggesting a deep discount or that the market assigns minimal value to the intangible assets and R&D pipeline relative to the recorded equity. Since price-to-sales and EV/EBITDA are also unavailable, alternative valuation approaches are required to assess the company's worth, as these standard metrics are typically used for mature companies with consistent earnings and sales streams. The stock traded with a 52-week high of $0.02 and a 52-week low of $0.01, placing the current trading range within a narrow band that reflects high volatility and speculative interest common in small-cap biotechnology stocks. The beta value of 0.50 suggests that the stock's price volatility is approximately half that of the broader market, indicating a lower sensitivity to general market movements but also potentially lower liquidity and higher idiosyncratic risk specific to the company's clinical outcomes.

Growth & Income

Revenue growth and earnings growth rates for the year-over-year period are not available in the provided facts, preventing a direct comparison of earnings expansion relative to revenue growth, though the consistent negative net income indicates that the company is not yet in a growth phase driven by profitability. As a non-dividend payer with no reported dividend yield or payout ratio, the company follows a standard biopharma model where earnings are effectively reinvested into growth initiatives such as clinical trials and regulatory submissions rather than distributed to shareholders. The overall growth and income profile is characterized by a lack of current income generation and a reliance on future commercial success of product candidates to transition from a cash-burning entity to a profitable business. This profile necessitates a long-term investment horizon where returns are contingent upon the successful commercialization of XYNGARI and other pipeline assets rather than short-term dividend yields or consistent earnings growth.